SCHEMBL17429705

SCHEMBL17429705

COC(=O)c1ccc2c(c1)-c1ccc(C)nc1CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
ALDH1A1 P00352 3/20 0.40
ATM Q13315 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPK14 Q16539 1/20 0.39
MAPT P10636 3/20 0.39
RAB9A P51151 5/20 0.39
TP53 P04637 1/20 0.39
MMP13 P45452 1/20 0.39
SPR P35270 1/20 0.38
NPC1 O15118 4/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17385912 0.88 LMNA (0.41) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17385788 0.86 ALDH1A1 (0.42) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17429647 0.79 TDP1 (0.47) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17429698 0.78 LMNA (0.37) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17417956 0.78 LMNA (0.38) LMNASMN1; SMN2ALDH1A1ATMKDM4E
SCHEMBL17386042 0.78 ALDH1A1 (0.38) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17400116 0.77 SPR (0.39) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17385898 0.77 ACHE (0.40) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17386203 0.76 HSD17B1 (0.49) LMNASMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL17418011 0.76 LMNA (0.37) LMNASMN1; SMN2ALDH1A1ATMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 LMNA 2845/4885SMN1; SMN2 3972/4885ALDH1A1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.